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Umbilical cord stroma mesenchymal stem cells were
differentiated toward chondrocyte-like cells using a new
in vitro model that consists of the random formation of
spheroids in a medium supplemented with fetal bovine
serum on a nonadherent surface. The medium was
changed after 2 days to one specific for the induction of
chondrocyte differentiation. We assessed this model us-
ing reverse transcriptase-polymerase chain reaction,
flow cytometry, immunohistochemistry, and secretome
analyses. The purpose of this study was to determine
which proteins were differentially expressed during
chondrogenesis. Differential gel electrophoresis analy-
sis was performed, followed by matrix-assisted laser
desorption/ionization mass spectrometry protein iden-
tification. A total of 97 spots were modulated during the
chondrogenesis process, 54 of these spots were identi-
fied as 39 different proteins and 15 were isoforms. Of the
39 different proteins identified 15 were down-regulated,
21 were up-regulated, and 3 were up- and down-regu-
lated during the chondrogenesis process. Using Path-
way Studio 7.0 software, our results showed that the
major cell functions modulated during chondrogenesis
were cellular differentiation, proliferation, and migra-
tion. Five proteins involved in cartilage extracellular ma-
trix metabolism found during the differential gel electro-
phoresis study were confirmed using Western blot. The
results indicate that our in vitro chondrogenesis model
is an efficient and rapid technique for obtaining cells
similar to chondrocytes that express proteins charac-
teristic of the cartilage extracellular matrix. These chon-
drocyte-like cells could prove useful for future cell ther-
apy treatment of cartilage pathologies. Molecular &
Cellular Proteomics 11: 10.1074/mcp.M111.010496, 1–
10, 2012.
Mesenchymal stem cells (MSCs)1 are undifferentiated cells
with unlimited self-renewal capacity found in most organs and
tissues of adult organisms. MSCs have proven to be a versa-
tile source of cells capable of differentiating into various cel-
lular lineages (1). MSCs have been isolated from a number of
organs or tissues including adipose tissue (2), muscle (3), and
umbilical cord (UC) (4). Our group has conducted proteome
studies of chondrocytes with diverse pathologies (5, 6) and
has also achieved differentiation toward chondrocyte-like
cells of MSCs from UC stroma using a new spheroid model
and defined chondrogenic medium (7). Our findings demon-
strate that MSCs from UC stroma are multipotent cells capa-
ble of differentiation into mesodermal and ectodermal cell
lineages (7). Various techniques, including immunohisto-
chemistry, reverse transcriptase-polymerase chain reaction
(RT-PCR), and one-dimensional SDS-PAGE (1D-SDS-PAGE)
coupled to nano liquid chromatography matrix-assisted laser
desorption/ionization (nano LC MALDI) time-of-flight (TOF)/
TOF yielded evidence of proteins and gene expressions char-
acteristic of native cartilage by these cells (7). The goal of the
study reported here was to quantify the proteome of MSCs of
human UC stroma (UCs) using differential gel electrophoresis
(DIGE) proteome analysis to identify key pathways involved in
our chondrogenic process that may prove useful for cell ther-
apy of cartilage pathologies.
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MATERIALS AND METHODS
Tissue Collection—Human UCs were obtained from caesarean
sections performed on 23 healthy women at the Maternity Facility at
Complejo Hospitalario Universitario A Corun˜a (CHUAC). All tissues
were obtained with fully informed consent and ethical approval by the
supervisor of the Ethical Committee (CEIC) of Galicia. All the women
were between 26 and 35 years-old.
Isolation and Culture of MSCs—MSCs were isolated from UCs
using the protocol developed by our group (4). Briefly, the tissue was
washed with phosphate buffered saline and cut into small pieces
(explants). These explants were then incubated for three five-minute
periods in an enzyme mixture containing 1.2 U/ml dispase and 112
U/ml type I collagenase (all from Sigma-Aldrich) and cultured in Dul-
beccos Modified Eagles Medium with 10% fetal bovine serum, 1%
penicillin, and 1% streptomycin (all from Sigma-Aldrich) and growth
adhered to the plastic plate. After 3 days, the explants were removed
from the plate, leaving the attached UC MSCs, which were then
cultured in monolayer in the same medium. When the cells
were 90% confluent, they were removed from the plate using 2%
trypsin (Sigma-Aldrich) in phosphate-buffered saline and induced to
differentiate toward chondrogenesis.
The MSCs were seeded into 96-well plates (Sarstedt, Inc., Barce-
lona, Spain) at 2  104 cells per well in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum, 1% penicillin, 1% streptomy-
cin, 1.5  104 M of monothioglycerol, 5 mg/ml ascorbic acid, and 6
g/ml transferrin (all from Sigma-Aldrich) to facilitate spontaneous
spheroid formation. The medium was then changed to a chondro-
genic medium, composed of Dulbecco’s modified Eagle’s medium
with 15% knockout serum (Invitrogen, Barcelona, Spain), 5 mg/ml
ascorbic acid, 6 g/ml transferrin, 10 M dexamethasone, 1  10–7
M retinoic acid and 1 ng/ml recombinant human transforming growth
factor-3 (ProSpec-Tany TechnoGene, Deltaclon, Madrid, Spain).
This medium was changed every 3 days. After 4, 7, 14, 28, and 46
days in the chondrogenic medium, spheroids were collected, frozen,
and stored at 4 °C for later analyses.
DIGE Sample Preparation and Labeling—Spheroids recovered
from the culture plates were washed twice with phosphate-buffered
saline. The spheroids were disaggregated using a Mixer Mill MM 200
(RESTCH, Haan, Germany) with zirconium balls in liquid nitrogen
followed by a one-hour incubation with gentle agitation in 200 l of
isolectric focusing-compatible lysis buffer containing 8.4 M urea, 2.4 M
thiourea, 5% 3-[(3-cholamidopropyl)dimethylammonio]propanesul-
fonate, 1% carrier ampholytes [imobilized pH gradient (IPG) buffer],
0.4% Triton X-100 and 2 mM dithiothreitol (Sigma-Aldrich) at pH 8 to
9. Total proteins in each lysate were quantified using the Bradford
protein assay (Sigma-Aldrich). The samples were labeled using fluo-
rescent Cy Dyes according to the manufacturer’s instructions (GE
Healthcare, Buckinghamshire, UK). Three chondrogenic differentia-
tions were used for each sample at each collection time. The sample
labeling is shown in Table I.
2D-Gel Electrophoresis—IPG strips (pH 3–11, 24 cm, Bio-Rad
Laboratories, Hercules, CA) were rehydrated with hydration buffer
(8.4 M Urea, 2 M thiourea, 2% 3-[(3-cholamidopropyl)dimethylammo-
nio]propanesulfonate, 0.02% bromphenol blue, 0.5% carrier ampho-
lytes, 1.2% Destreak (GE Healthcare) for 18 h at room temperature.
Cy Dye-labeled samples were loaded into a cap-load covered with
Cover Fluid (GE Healthcare) and isoelectric focusing was performed
for a total of 95,000 Vh for 24 cm strips using the IPGphor-II appa-
ratus (GE Healthcare). The strips were equilibrated prior to SDS-
PAGE for 15 min in equilibration buffer (6 M urea, 50 mM Tris pH 8.8,
20% (v/v) glycerol, 2% (w/v) SDS) with 1% (v/v) dithiotreitol, then for
an additional 15 min in the same equilibration buffer with 4% (v/v)
iodine acetamine. The strips were overlaid with 1% agarose in SDS
running buffer containing bromphenol blue. Tris-glycine running
buffer (24.8 mM Tris, 192 mM glycine, 0.1% (w/v) SDS) was used. The
24-cm gels were run on a Criterion gel system (Bio-Rad Laboratories)
for the second dimension until the dye front passed the bottom of the
gel. The gels were immediately scanned. A non-DIGE preparative gel
was run with 500 g protein from a pool of all samples under the
same conditions. This gel was stained with Coomassie blue and spots
were excised for protein identification.
Gel Imaging—The gels were scanned using a Typhoon9410 scan-
ner (GE Healthcare) following the manufacturer’s instructions. Image
analysis was performed using the DeCyder software package version
5 (GE Healthcare), a 2-DE analysis software specifically designed for
DIGE experiments. [1370 spots were identified and quantified using
the DeCyder difference in-gel analysis (DIA) module. Proteins were
deemed to be differentially expressed if they showed a greater than
1.5-fold change in abundance and if p  0.05 was found using a
1-way ANOVA. Ninety-seven spots were observed to be modulated.
MS Analysis—The samples were first reduced using dithiotreitol,
then alkylated with iodoacetamide and digested at 37 °C using 6.66
ng/l sequencing-grade trypsin (Roche Molecular Biochemicals, In-
dianapolis, IN). Following digestion, the supernatant was collected
and a 1 l spot placed on a MALDI target plate (ABSciex, Framing-
ham, MA) and allowed to air-dry at room temperature. When dried,
0.5 l of a 3 mg/ml solution of -cyano-4-hydroxy-trans-cinnamic
acid matrix in 0.1% trifluroacetic acid-50% acetonitrile was added to
the dried peptide spots and allowed to air-dry. The samples were
analyzed using the MALDI-TOF/TOF mass spectrometer 4800 Pro-
teomics Analyzer (ABSciex, Framingham, MA) and 4000 Series Ex-
plorer™ Software (ABSciex). MALDI-TOF spectra were acquired in
reflector positive-ion mode using 1000 laser shots per spectrum. Data
Explorer version 4.2 (ABSciex) was used for spectra analyses and
generating peak-picking lists. All mass spectra were internally cali-
brated using autoproteolytic trypsin fragments and externally cali-
brated using a standard peptide mixture 4700 CAL MIX (ABSciex).
TOF/TOF fragmentation spectra were acquired by selecting the 20
most abundant ions of each MALDI-TOF peptide mass map, exclud-
ing trypsin autolytic peptides and other known background ions,
using an average of 1500 laser shots per fragmentation spectrum. The
parameters utilized for analysis were a signal to noise threshold of 20,
a minimum area of 100 and a resolution higher than 10,000 with a
mass accuracy of 20 ppm.
Database Search—The amino acid sequence tag obtained from
each peptide fragmentation in MS/MS analyses were used to search
for protein candidates using Mascot online 2.0 as search engine
(www.matrixscience.com). Peak intensity was used to select up to 50
peaks per spot for peptide mass fingerprinting, and 50 peaks per
precursor for MS/MS identification. Tryptic autolytic fragments, ker-
atin, and matrix-derived peaks were removed from the data used for
the search. The searches for peptide mass fingerprints and tandem
MS spectra were performed in the Swiss-Prot release 53.0 database
(269.293 entries) without taxonomy restriction. Fixed and variable
modifications were considered (Cys as carbamidomethyl derivate and
Met as oxidized methionine, respectively), allowing one trypsin-
missed cleavage site and a mass tolerance of 50 ppm. For MS/MS
identifications, a precursor tolerance of 50 ppm and MS/MS frag-
ments tolerance of 0.3 Da were used. Identification was accepted as
positive when at least two peptides matched and at least 10% of the
peptide coverage of the theoretical sequences matched within a
mass accuracy of 50 or 25 ppm with internal calibration. Probability
scores were significant at p 0.01 for all matches. Proteins of interest
were excised from the preparative gel for protein identification. Prep-
aration for protein identification used the protocol from Gez et al. (8).
Protein Isolation and Immunoblot Analysis—Immunoblot analysis
was performed using 40 g of total protein extracted from cells in
culture, as previously described (9). The blots were probed with
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antibodies directed against human superoxide dismutase mitochon-
drial (SODm), protein disulfide-isomerase A1 (PDIA), 78 kDa glucose-
regulated protein (GRP78), peptidyl-prolyl cis-trans isomerase A
(PPIA), heat shock protein HSP90-beta (HSP90), procollagen-lysine
(PLOD2) (all from Santa Cruz Biotechnology, Santa Cruz, CA) and
glycerol-3-phosphate dehydrogenase (GAPDH) (Sigma-Aldrich). A
secondary anti-mouse antibody (Santa Cruz Biotechnology) was used
to visualize proteins using an Amersham BiosciencesTM ECLTM West-
ern blotting analysis system (GE Healthcare, Amersham Biosciences
Biotechnology, UK). Ideal concentrations for each antibody were
determined empirically. Working concentrations were 1:1000 of the
recommended stock solutions. Three experiments were performed.
One of them was a pool from the DIGE/MS analysis and the other two
were from other random experiments.
Real-time Reverse Transcriptase PCR (qRT-PCR) Analysis—The
reported sequences of genes for human SODm (forward: CTGGAC-
AAACCTCAGCCCTA; reverse: TGATGGCTTCCAGCAACTC), PDIA
(forward: TTGGCCTCACCAAGGACA; reverse: TGACCAGGAAGCG-
CGACA), GRP78 (forward: GGATCATCAACGAGCCTACG; reverse:
CACCCAGGTCAAACACCAG), PPIA (forward: ATGCTGGACCCAAC-
ACAAAT; reverse: TCTTTCACTTTGCCAAACACC), HSP90 (forward:
CGTTGCTCACTATTACGTATAATCCT; reverse: TGCCTGAAAGGCA-
AAAGTCT), PLOD2 (forward: TCATGGACACAGGATAATGGCTGCA;
reverse: AGGTAGAAAAGGGGTTGGTTGCTCA), and 50S ribosomal
protein L16 (RPLP) (forward: TCTACAACCCTGAAGTGCTTGAT; re-
verse: CAATCTGCAGACAGACACTGG) as housekeeping were used
for primer design. The amplification program consisted of an initial
denaturation at 92 °C for 2 min followed by 40 cycles from 92 °C for
15 s, annealing at 61 °C for 30 s, and an extension at 72 °C for 15 s.
Each PCR analysis was performed in duplicate, with each set of
assays repeated three times. To minimize effects of unequal quanti-
ties of starting RNA and to eliminate potential sources of inconsis-
tency, relative expression levels of each gene were normalized to
RPLP using the 2-Ct method (10). Control experiments contained
no reverse transcriptase.
RESULTS
All proteins from chondrocyte-like cells were compared
with proteins secreted by undifferentiated cells at time point 0.
Twelve differentiations of MSCs from human UC stroma do-
nors were achieved. Representative images of the chondro-
genic process identified using immunohistochemistry against
human collagen type II (COL2) for each collection time are
shown in Fig. 1A.
Three pools from three differentiation experiments were
combined to perform three different DIGE analyses (Table I).
1370 spots were detected, 97 of which were significant at p
FIG. 1. Chondrogenesis model. A, Experimental plan indicating which days of chondrogenesis were used for differential-in-gel electro-
phoresis (DIGE) analyses. Representative immunohistochemical images of the expression of collagen type II (COL2) from spheroids engineered
from umbilical stroma mesenchymal stem cells collected at different time points before DIGE analysis are shown at the top (Magnification 10).
B, Graph showing modulated proteins (previously identified as directly associated with the native cartilage extracellular matrix or chondrocytes)
identified by mass spectroscopy during the chondrogenesis process at 4 and 46 days and their expression relative to that found in
undifferentiated cells at time 0. They were listed in order from lowest to highest.
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0.01 (one way ANOVA). From the 97 spots, 54 proteins were
identified by MS/MS (Table II). All modulated 54 proteins
expressed during the chondrogenesis process were up- or
down-regulated as early as 4 days of culture in chondrogenic
medium. From a total of 97 proteins modulated during chon-
drogenesis differentiation, 15 were down-regulated, 21 were
up-regulated, and three were down-regulated at the begin-
ning of chondrogenesis and up-regulated at the final of pro-
cess (Table III). Interestingly, from all modulated proteins 12
have been identified in the literature as characteristic proteins
of the chondrogenesis process or as directly associated with
the native cartilage extracellular matrix (ECM) or chondro-
cytes (Table III). PDIA3, SOD2, ZYX, and PLOD2 were clearly
up-regulated during chondrogenesis at 4 and 46 days
(Fig. 1B).
Principal component analysis was used to determine
whether the proteomic profile obtained from our chondrogen-
esis model was homogenous. Proteomic maps were utilized
for variables and spots from the different groups were used as
observations in “score graphs.” Score graphs are useful for
reducing complexity and obtaining a simplified examination of
proteomic spots. Score graphs can be used to determine
whether the samples express a similar proteomic profile and
whether the spots belong to the same experimental group.
Fig. 2A shows that day 0 spots (pink) were much closer to
each other and situated at one side of the graph, whereas day
46 spots (green) were clustered at the opposite side. Spots
corresponding to the intermediate differentiation days are
situated between these positions. Plotting these data using
the same variable on both axes to make the data linear did not
change the proteomic profile (Fig. 2B). These results indicated
that our data were very homogeneous with no discordant data
affecting the statistical analysis.
The major proteins found in our chondrogenesis model after
day 4 of differentiation were grouped according to three pri-
mary cell functions. In cellular proliferation were annexins 1
(ANXA1) and 6 (ANXA6), heat shock 70 kDa protein 14
(HSP70), caldesmon (CALD1), transgeline (TAGL), and zyxin
(ZYX), all up-regulated. Proteins involved in cell differentiation
were peptidyl-prolyl cis-trans isomerase A (PPIA), heat shock
90 kDa protein (HSP90) and glutathione S-transferase P
(GSTP1), all down-regulated. Proteins involved in cell migra-
tion were protein disulfide-isomerase A1 (PDIA1) and nucleo-
side diphosphate kinase A (NME1), which were down-regu-
lated. The modulated proteins grouped according to cell
function were examined and we found that those involved in
cell organization were 45% of the total modulated proteins,
followed by of 19% involved in reduction-oxidation stress,
16% in metabolism and 7% in signal transduction (Fig. 3).
The expression of six representative proteins was deter-
mined throughout chondrogenesis in our model using immu-
noblot analysis to validate the results from the DIGE tech-
nique. SODm, GRP78, and PLOD2 increased their expression
at 4 days and continued to increase throughout the differen-
tiation process. PDIA1, PPIA, and HSP90 were decreased at
4 days and continued decreasing throughout (Fig. 4A). These
results confirm the results obtained from the DIGE analyses.
Gene expressions for each protein was analyzed by qRT-PCR
during chondrogenic process and they were coincident with
their protein levels for the different times of chondrogenic
differentiation found by DIGE and validated by immunoblot-
ting (Fig. 4B).
DISCUSSION
Over the past year, our group has reported proteomic stud-
ies of chondrocytes in various pathologies and under differing
culture conditions (11). This is the first report of a study of
chondrogenic differentiation of MSCs from a novel source, the
UC stroma. DIGE has previously been used to analyze osteo-
blast differentiation from MSCs of adipose tissue (12) and to
study nuclear proteomes from human embryonic and MSCs
(13). However, to our knowledge, our study is the first one
using DIGE to study the proteome of UC MSCs undergoing
chondrogenic differentiation at six different time points (0, 4,
7, 14, 28, and 46 days) (Fig. 1). This approach represents a
new global comparative proteomics approach with broad ap-
plications for basic and clinical biological sciences. Our pri-
mary goal was to identify pathways involved in chondrogen-
esis to validate and improve our in vitro chondrogenic model
(4) with our ultimate objective being to develop new therapies
for cartilage degeneration pathologies.
The principal components analysis results indicated that
our data were very homogeneous with no discordant data
affecting the statistical analysis (Fig. 2). The modulated pro-
teins were either up- or down-regulated in the directed me-
dium at all the time points from 4 days to 46 days, with
significant differences found mainly between undifferentiated
TABLE I
Samples used for the differential gel electrophoresis (DIGE) analysis.
Mesenchymal stem cells from 12 donors were differentiated toward
chondrocyte-like cells. The top of the table indicates the amount of
protein used in DIGE experiments labeled with Cy2, Cy3, or Cy5 dye.
The first column indicates the gel number; the following columns indi-
cate the days in differentiation medium charged in the gel. Three differ-
ent experiments were performed and are indicated as *, , and . Each
experiment utilized a pool of three chondrogenic differentiations from
three different donors. Standard is the mix of same amount of protein of
each condition
Cy2 (50 g) Cy3 (50 g) Cy5 (50 g)
GEL1 Standard 0* 4*
GEL2 Standard 7* 14*
GEL3 Standard 28* 46*
GEL4 Standard 4 0
GEL5 Standard 14 7
GEL6 Standard 46 28
GEL7 Standard 0 4
GEL8 Standard 7 14
GEL9 Standard 28 46
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TABLE II
Proteomic analysis at different times of chondrogenesis from mesenchymal stem cells (MSCs) from human umbilical cord stroma using a
two-dimensional DIGE technique coupled to MALDI-TOF/TOF. Only those proteins modulated during chondrogenesis identified by at least two
specific human peptides with confidence 99% are included in the list
NAME MSMS match Location Score
# ID
peptides
Spot p anova
Annexin A2 ANXA2_HUMAN Extracellular matrix 973 15 775 2.58E-01
Peroxiredoxin-5 PRDX5_HUMAN Mitochondrion 475 7 565 6.73E-01
GRP78 GRP78 Endoplasmic reticulum 772 17 656 0.001
Protein disulfide-isomerase A3 PDIA3_HUMAN Endoplasmic reticulum 872 13 675 0.001
Tropomyosin beta chain TPM2_HUMAN Cytoplasm 190 4 759 0.002
Transgelin TAGL_HUMAN Cytoplasm 673 15 637 0.002
Heat shock protein, mitochondrial CH60_HUMAN Mitochondrion 75 3 1091 0.002
Vimentin VIME_HUMAN Intermediate filament 252 9 751 0.002
Protein DJ-1 PARK7_HUMAN Nucleus 270 9 833 0.003
Protein SET SET_HUMAN Endoplasmic reticulum 66 2 693 0.003
Calreticulin CALR_HUMAN Endoplasmic reticulum 551 8 578 0.003
Reticulocalbin-3 RCN3_HUMAN Endoplasmic reticulum 423 7 655 0.004
Annexin A5 ANXA5_HUMAN Extracellular matrix 644 12 788 0.004
Annexin A1 ANXA1_HUMAN Extracellular matrix 1329 15 776 0.004
Transgelin TAGL_HUMAN 371 15 1089 0.005
Annexin A1 ANXA1_HUMAN Extracellular matrix 1029 15 772 0.005
Heat shock protein beta-1 HSPB1_HUMAN Cytoplasm 585 8 849 0.005
Endoplasmin ENPL_HUMAN Endoplasmic reticulum 542 12 526 0.005
Annexin A6 ANXA6_HUMAN Extracellular matrix 708 3 391 0.005
Procollagen-lysine PLOD2_HUMAN Endoplasmic reticulum membrane 184 3 221 0.008
Reticulocalbin-1 RCN1_HUMAN Endoplasmic reticulum 187 4 695 0.008
Stress-induced-phosphoprotein 1 STIP1_HUMAN Cytoplasm & nucleus 122 5 671 0.008
Peptidyl-prolyl cis-trans isomerase A PPIA_HUMAN Cytoplasm 550 8 1250 0.009
Annexin A1 ANXA1_HUMAN Extracellular matrix 874 15 632 0.009
Peptidyl-prolyl cis-trans isomerase A PPIA_HUMAN Cytoplasm 508 8 1285 0.011
Annexin A5 ANXA5_HUMAN Extracellular matrix 691 12 1081 0.011
Zyxin ZYX_HUMAN Cytoplasm & nucleus 206 6 186 0.011
Annexin A2 ANXA2_HUMAN Extracellular matrix 396 13 783 0.013
Superoxide dismutase SODM_HUMAN Mitochondrion 391 5 864 0.014
Phosphoglycerate mutase 1 PGAM1_HUMAN Cytoplasm 381 8 843 0.015
Ubiquitin carboxyl-terminal hydrolase
isozyme L1
UCHL1_HUMAN Cytoplasm 223 8 896 0.017
Ferritin light chain FRIL_HUMAN Cytoplasm 130 4 1305 0.017
Nucleoside diphosphate kinase A NDKA_HUMAN Cytoplasm & Nucleus 269 6 1278 0.018
Annexin A2 ANXA2_HUMAN Extracellular matrix 492 13 781 0.019
Superoxide dismutase SODM_HUMAN Mitochondrion 130 5 1082 0.020
Protein disulfide-isomerase A3 PDIA3_HUMAN Endoplasmic reticulum 457 13 672 0.031
Tyrosyl-tRNA synthetase, cytoplasmic SYYC_HUMAN Cytoplasm 64 2 469 0.033
Glyceraldehyde-3-phosphate
dehydrogenase
G3P_HUMAN Membrane 62 3 509 0.033
Transgelin-2 TAGL2_HUMAN Membrane 809 14 1075 0.033
Heat shock protein beta-1 HSPB1_HUMAN Cytoplasm & Nucleus 405 8 978 0.034
Nicotinamide N-methyltransferase NNMT_HUMAN Cytoplasm 486 10 873 0.034
Calumenin CALU_HUMAN Endoplasmic reticulum 448 7 680 0.035
Peroxiredoxin-6 PRDX6_HUMAN 381 7 848 0.039
Annexin A5 ANXA5_HUMAN Extracellular matrix 277 12 634 0.039
Triosephosphate isomerase TPIS_HUMAN Cytoplasm 1061 14 858 0.039
Alpha-enolase ENOA_HUMAN 631 9 650 0.040
Annexin A2 ANXA2_HUMAN Extracellular matrix 643 13 774 0.043
Glutathione S-transferase P GSTP1_HUMAN Cytoplasm 439 6 951 0.045
Caldesmon CALD1_HUMAN Plasma membrane 280 8 283 0.046
Vimentin VIME_HUMAN Intermediate filament 193 9 673 0.046
Protein disulfide-isomerase A1 PDIA1_HUMAN Endoplasmic reticulum 1045 13 616 0.046
Protein disulfide-isomerase A3 PDIA3_HUMAN Endoplasmic reticulum 543 13 615 0.048
Heterogeneous nuclear
ribonucleoprotein D-like
HNRDL_HUMAN Cytoplasm & Nucleus 204 4 770 0.048
Caldesmon CALD1_HUMAN Plasma membrane 267 8 275 0.050
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time 0 MSCs and the chondrocyte-like cells after 4 days of
differentiation (Table III). Recent studies have shown that
MSCs are capable of differentiation toward chondrocyte-like
cells as soon as 3 days under appropriate culture conditions
(14) and are able to maintain this differentiated stage for a long
time in these culture conditions. That the modulated proteins
in our study retain either the up or down-regulation through-
out the chondrogenic process indicates the consistency of
our model and corroborates the results obtained in the prin-
cipal components analysis. Proteins involving cell organiza-
tion processes were the most abundant when we grouped the
modulated proteins by function at 45% of the total modulated
protein (Fig. 3), followed by proteins involved in stress-related
mechanisms at 19%. These results are consistent with cellu-
TABLE III
Modulated proteins identified by MALDI-TOF/TOF during chondrogenesis using our spheroid model. The first column on the left lists the name
of the protein and the top line shows the days of differentiation. The numbers indicate the score. The controls (undifferentiated cells at time 0)
were assigned the number 1; therefore proteins with scores1 were down-regulated and those with scores1 were up-regulated. The shaded,
colored boxes indicate proteins found in cartilage or chondrocytes with the literature source citation
Name/diff day 4 7 14 28 46 Source
HSP90B1 0.1 0.1 0.1 0.1 0.2 (Ruiz-Romero C. et al. 2010)
PPIA 0.2 0.2 0.1 0.1 0.1 (Satoh et al. 2009)[1]
Calumenin 0.4 0.3 0.1 0.2 0.2 (Coppinger et al. 2004)[2]
FTL 0.3 0.3 0.2 0.2 0.1
ANXA5 0.4 0.3 0.2 0.1 0.1 (Ulbrich et al. 2010)[3]
SET 0.3 0.2 0.2 0.3 0.3
NME1 0.3 0.5 0.3 0.2 0.2
CALR3 0.2 0.2 0.3 0.2 0.3 (Van Duyn Graham et al. 2010)[4]
RCN3 0.2 0.3 0.3 0.2 0.1
RCN1 0.3 0.3 0.3 0.3 0.2
PRDX5 0.3 0.3 0.3 0.2 0.2
PDIA1 0.3 0.6 0.3 0.3 0.3 (Ruiz-Romero C. et al. 2010)
VIM 0.5 0.5 0.4 0.4 0.4 (Bobick et al. 2010)[5]
GSTP1 0.6 0.5 0.4 0.5 0.5
PGAM1 0.6 0.6 0.8 0.8 2.5
GRP78 0.6 1.2 1.2 2.4 2.7 (Calamia V. et al. 2010)
PRDX6 1.0 1.0 0.9 1.0 2.4
TPI1 0.8 0.9 1.0 0.8 2.2
HSPA5 0.7 1.2 1.3 2.7 3.0
HSPB1 1.0 1.1 1.1 1.5 2.0
ENO1 1.0 1.0 1.1 1.1 1.9
PHGDH 1.6 1.4 1.1 1.4 1.9
STIP1 1.4 1.6 1.2 1.6 3.2
PDIA3 1.6 1.6 1.4 1.8 3.0 (Boyan and Schwartz 2009)
NNMT 2.0 2.3 1.5 2.0 3.3
HNRPDL 2.8 2.3 1.5 1.5 2.8
ANXA2 1.7 2.0 1.7 2.0 5.3
UCHL1 2.0 2.0 1.8 1.8 4.0
SODm 2.7 2.3 2.0 3.0 4.7 (Kim et al. 2010)[6]
YARS 1.3 1.8 2.0 2.2 1.7
ADAM15 3.0 3.2 2.2 1.8 1.8
ANXA1 2.3 2.0 2.3 2.0 3.5
HSPD1 1.7 2.3 2.3 3.0 4.7
TAGLN2 1.7 2.3 2.3 2.3 4.3
ANXA6 4.2 4.4 3.0 3.0 3.8
CALD1 3.5 2.3 3.8 6.6 3.2
TAGLN 3.0 3.5 4.5 5.0 6.5
ZYX 4.7 4.0 4.7 3.7 4.0 (Hirsch et al. 1996, Petroll and Ma 2003)[7]
PLOD2 7.0 5.5 5.0 3.5 5.0 (van den Bogaerdt et al. 2009)[8]
[1] Not in ref list.
[2] Not in ref list.
[3] Not in ref list.
[4] Not in ref list.
[5] Not in ref list.
[6] Not in ref list.
[7] Not in ref list.
[8] Not in ref list.
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lar changes shown experimentally in MSCs during the differ-
entiation process.
The goal of this study was identify novel proteomic changes
during chondrocyte development using a human cell model
for chondrogenesis validated previously by our group (7).
Results demonstrate that mesenchymal stem cells cultured in
the chondrogenic medium become chondrocyte-like, as cells
express protein observed in differentiated chondrocytes or in
cartilage (Table II). Six proteins from all proteins modulate
during chondrogenesis were validated by qRT-PCR and
Western blot analysis. These proteins were SODm, PDIA,
GRP78, PPIA, HSP90, and PLOD2, all of which have been
previously identified in human chondrocytes (15). The West-
ern blot and real-time reverse transcriptase PCR (qRT-PCR)
results validate the results obtained by DIGE analysis (Fig. 4).
The results for each protein were maintained independent of
donor or analysis used.
Modulated proteins found to be up-regulated were procol-
lagen-lysine (PLOD2), which stabilizes the synthesis of colla-
gen type I and II and is involved in the chondrocytic response
to TNF--mediated stimuli affecting cartilage homeostasis
(16), enolase (ENO1), which increases hypoxia tolerance and
is involved in glycolysis (17), Heat shock protein beta-1
(HSPB1), which increases cell survival in changing environ-
FIG. 2. Principal components analysis of differential-in-gel electrophoresis (DIGE) data. Scores graphs combining proteomic maps
(variables) and spots from different groups (observations) were constructed. A, Principal components analysis clustered the nine individual
Cy3- and Cy5-labeled expression maps into six different groups. Principal component 1 was 66.75% from the modulated proteins and principal
component 2 was 14.32% from the modulated proteins. B, Principal component 1 was 66.75%.
FIG. 3. Cellular functions during chondrogenesis. The graph rep-
resents the percentage of modulated proteins found in our chondro-
genesis model involved in the main cellular functions.
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ments (18), superoxide dismutase (SODm), which destroys
free radicals (a reduction in SODm is associated with the
earliest stages of osteoarthritis in an animal model) (19), and
zyxin (ZYX), which is involved in signaling pathways. Recent
research elaborated by our group revealed that overexpres-
sion of Lamin A leads to defects in differentiation potential of
MSCs. The chondrogenic potential is defective in Lamin A-
MSCs, and this lineage has an increase in hypertrophy mark-
ers during chondrogenic differentiation, as well as a decrease
in manganese superoxide dismutase and an increase of mi-
tochondrial manganese superoxide dismutase-dependent re-
active oxygen species. Interestingly, defects in chondrogen-
esis are partially reversed by periodic incubation with a
SODM-mimic agent, supporting the idea that the effect of
Lamin A on chondrogenesis could be because it increases
reactive oxygen species levels (20).
The proteins we found to be down-regulated were calreti-
culin, which is involved in processing and transport of wild
type cartilage oligomeric matrix protein in normal chondro-
cytes and in the retention of mutant cartilage oligomeric ma-
trix protein in pseudoachondroplasic chondrocytes (21),
PDIA, which in low quantities increases protein aggregation
and is involved in ECM formation (22), and vimentin, which is
abundantly expressed in MSCs. The disruption of vimentin
reduces stiffness 2.8-fold in normal chondrocytes, but os-
teoarthritic chondrocytes are less stiff and less affected by
vimentin disruption (23). This three-dimensional experimental
system revealed contributions of vimentin to chondrocyte
FIG. 4. Validation of six representative proteins found to be modulated during chondrogenesis. A, Western blot at 0, 4, 7, 14, 28,
and 46 days in chondrogenic medium of each protein. The density value of each band was normalized to the GAPDH level and expressed
relative to the control, shown as fold-induction written under each band. B, Histogram represents gene expression of each protein by
Real-time reverse transcriptase PCR (qRT-PCR) analysis normalized by expression of RPLP gene, which was taken as housekeeping.
Superoxide dismutase mitochondrial 	 SODm; Protein disulfide-isomerase A1, PDIA; 78kDa glucose-regulated protein, GRP78; Peptidyl-
prolyl cis-trans isomerase A, PPIA; Heat shock protein HSP90-beta, HSP90; Procollagen-lysine, PLOD2; Glycerol-3-phosphate dehydro-
genase, GAPDH. The sample used for the representative western shown was a pool from the DIGE/MS analysis. Three replicates were
made.
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stiffness not previously apparent, and correlated changes in
vimentin-based chondrocyte stiffness with osteoarthritis (23).
Some of the modulated proteins found by our DIGE analysis
were involved in ossification, such as PARK7, which was
down-regulated indicating that our model did not produce
cellular hypertrophy (24). The up-regulation of ANXA2, ANX6,
and ANXA1, and the down-regulation of ANXA5 indicate that
chondrogenesis prevailed over osteogenesis (25) (Fig. 5).
These results are logical in consideration that in our chondro-
genic model undifferentiated MSCs at the beginning required
proliferation before the process to change them into chondro-
cyte-like cells as a second step.
Our study of the role of zyxin and its mechanism to maintain
mechanical homeostasis during the differentiation process
from MSCs to chondrocyte-like cells is of particular interest. It
is known that cells recognize and respond to changes in
cytoskeletal integrity and zyxin could be performing this func-
tion. A recent study showed that actin stress fibers undergo
local, acute, force-induced elongation and thinning events
that compromise their stress transmission function, followed
by stress fiber repair that restores this capability (26). Zyxin
promoted recruitment of the actin regulatory proteins, -ac-
tinin and Vasopresine, in compromised stress fiber zones (26),
their findings demonstrate a mechanism for rapid repair
and maintenance of the structural integrity of the actin
cytoskeleton.
We conclude that MSCs differentiating toward chondro-
cyte-like cells express proteins characteristic of the native
cartilage ECM. We have demonstrated that our in vitro chon-
drogenic model could be used for a variety of cell-based
transplantation and tissue engineering studies. All these ex-
periments are very relevant in the rheumatic disease field
because a good in vitro model is necessary to study this
pathology, which it is not accessible at present.
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FIG. 5. Relationships among proteins modulated during chondrogenesis. Graphic generated by Pathway Study 2 for PC software
showing linked bibliographic information among the proteins found in our model directly involved in the native cartilage extracellular matrix, or
chondrocytes. Proteins found to be up-regulated in our model are in red and those down-regulated are in blue. Functions and structures are
in the rectangles and the yellow color indicates catabolism.
Proteome Analysis During Chondrogenesis
Molecular & Cellular Proteomics 11.2 10.1074/mcp.M111.010496–9
REFERENCES
1. Duca, M., Dozza, B., Lucarelli, E., Santi, S., Di Giorgio, A., and Barbarella,
G. (2010) Fluorescent labeling of human mesenchymal stem cells by
thiophene fluorophores conjugated to a lipophilic carrier. Chem. Com-
mun. 46, 7948–7950
2. Pacho´n-Pen˜a, G., Yu, G., Tucker, A., Wu, X., Vendrell, J., Bunnell, B., and
Gimble, J. (2010) Stromal stem cells from adipose tissue and bone
marrow of age matched female donors display distinct immunopheno-
typic profiles. J. Cell. Physiol. 246, 843–851
3. Torsney, E., and Xu, Q. (2011) Resident vascular progenitor cells. J Mol Cell
Cardiol. 2, 304–311
4. Nishiyama, N., Miyoshi, S., Hida, N., Uyama, T., Okamoto, K., Ikegami, Y.,
Miyado, K., Segawa, K., Terai, M., Sakamoto, M., Ogawa, S., Umezawa,
A., The significant cardiomyogenic potential of human umbilical cord
blood-derived mesenchymal stem cells in vitro. Stem Cells 2007; 25:
2017–2024
5. Ruiz-Romero, C., Calamia, V., Rocha, B., Mateos, J., Ferna´ndez-Puente,
P., and Blanco, F. J. (2010) Hypoxia conditions differentially modulate
human normal and osteoarthritic chondrocyte proteomes. J. Proteome
Res. 9, 3035–3045
6. Cillero-Pastor, B., Ruiz-Romero, C., Carame´s, B., Lo´pez-Armada, M. J.,
and Blanco, F. J. (2010) Proteomic analysis by two-dimensional electro-
phoresis to identify the normal human chondrocyte proteome stimulated
by tumor necrosis factor alpha and interleukin-1beta. Arthritis Rheum.
62, 802–814
7. Arufe, M. C., De la Fuente, A., Mateos, J., Fuentes, I., De Toro, F. J., and
Blanco, F. J. (2010) Analysis of the Chondrogenic Potential and Secre-
tome of Mesenchymal Stem Cells Derived from Human Umbilical Cord
Stroma. Stem Cells Dev. 2011 Jul; 20(7): 1199–1212
8. Gez, S., Crossett, B., and Christopherson, R. I. (2007) Differentially ex-
pressed cytosolic proteins in human leukemia and lymphoma cell lines
correlate with lineages and functions. Biochim. Biophys. Acta 1774,
1173–1183
9. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and
Kato, J. Y. (1994) D-type cyclin-dependent kinase activity in mammalian
cells. Mol. Cell. Biol. 14, 2066–2076
10. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(-Delta Delta C(T))
Method. Methods 25, 402–408
11. Calamia, V., Ruiz-Romero, C., Rocha, B., Ferna´ndez-Puente, P., Mateos,
J., Montell, E., Verge´s, J., and Blanco, F. J. (2010) Pharmacoproteomic
study of the effects of chondroitin and glucosamine sulfate on human
articular chondrocytes. Arthritis Res. Ther. 12, R138
12. Giusta, M. S., Andrade, H., Santos, A. V., Castanheira, P., Lamana, L.,
Pimenta, A. M., and Goes, A. M. (2010) Proteomic analysis of human
mesenchymal stromal cells derived from adipose tissue undergoing os-
teoblast differentiation. Cytotherapy 12, 478–490
13. Jaishankar, A., Barthelery, M., Freeman, W. M., Salli, U., Ritty, T. M., and
Vrana, K. E. (2009) Human embryonic and mesenchymal stem cells
express different nuclear proteomes. Stem Cells Dev. 18, 793–802
14. Rothenberg, A. R., Ouyang, L., and Elisseeff, J. H. (2010) Mesenchymal
stem cell stimulation of tissue growth depends on differentiation state.
Stem Cells Dev. 2011 Mar; 20(3): 405–414
15. Lires-Dea´n, M., Carame´s, B., Cillero-Pastor, B., Galdo, F., Lo´pez-Armada,
M. J., and Blanco, F. J. (2008) Anti-apoptotic effect of transforming
growth factor-beta1 on human articular chondrocytes: role of protein
phosphatase 2A. Osteoarthritis Cartilage 16, 1370–1378
16. Ah-Kim, H., Zhang, X., Islam, S., Sofi, J. I., Glickberg, Y., Malemud, C. J.,
Moskowitz, R. W., and Haqqi, T. M. (2000) Tumour necrosis factor alpha
enhances the expression of hydroxyl lyase, cytoplasmic antiproteinase-2
and a dual specificity kinase TTK in human chondrocyte-like cells. Cy-
tokine 12, 142–150
17. Ruiz-Romero, C., Carreira, V., Rego, I., Remeseiro, S., Lo´pez-Armada,
M. J., and Blanco, F. J. (2008) Proteomic analysis of human osteoarthritic
chondrocytes reveals protein changes in stress and glycolysis. Proteom-
ics 8, 495–507
18. Lambrecht, S., Dhaenens, M., Almqvist, F., Verdonk, P., Verbruggen, G.,
Deforce, D., and Elewaut, D. (2010) Proteome characterization of human
articular chondrocytes leads to novel insights in the function of small
heat-shock proteins in chondrocyte homeostasis. Osteoarthritis Carti-
lage 18, 440–446
19. Scott, J. L., Gabrielides, C., Davidson, R. K., Swingler, T. E., Clark, I. M.,
Wallis, G. A., Boot-Handford, R. P., Kirkwood, T. B., Talyor, R. W., and
Young, D. A. (2010) Superoxide dismutase downregulation in osteoar-
thritis progression and end-stage disease. Ann. Rheum. Dis. 69,
1502–1510
20. Mateos J, De la Fuente A, Lesende-Rodriguez L, Arufe MC, Blanco FJ.
Lamin A deregularion in human mesenchymal stem cells promotes an
impairment in their chondrogenic potential and imbalance in their re-
sponse to oxidative stress. Arthritis Rheumatism, 2011 (in revision)
21. Hecht, J. T., Hayes, E., Snuggs, M., Decker, G., Montufar-Solis, D., Doege,
K., Mwalle, F., Poole, R., Stevens, J., and Duke, P. J. (2001) Calreticulin,
PDI, Grp94 and BiP chaperone proteins are associated with retained
COMP in pseudoachondroplasia chondrocytes. Matrix Biol. 20, 251–262
22. Boyan, B. D., and Schwartz, Z. (2009) 1,25-Dihydroxy vitamin D3 is an
autocrine regulator of extracellular matrix turnover and growth factor
release via ERp60-activated matrix vesicle matrix metalloproteinases.
Cells Tissues Organs. 189, 70–74
23. Haudenschild, D. R., Chen, J., Pang, N., Steklov, N., Grogan, S. P., Lotz,
M. K., and D’Lima, D. D. (2011) Vimentin contributes to changes in
chondrocyte stiffness in osteoarthritis. J. Orthop. Res. 29, 20–25
24. Shim, S., Kwon, Y. B., Yoshikawa, Y., and Kwon, J. (2008) Ubiquitin
C-terminal hydrolase L1 deficiency decreases bone mineralization. J.
Vet. Med. Sci. 70, 649–651
25. Wang, W., Xu, J., and Kirsch, T. (2005) Annexin V and terminal differenti-
ation of growth plate chondrocytes. Exp. Cell Res. 305, 156–165
26. Smith, M. A., Blankman, E., Gardel, M. L., Luettjohann, L., Waterman, C. M.,
and Beckerle, M. C. (2010) A zyxin-mediated mechanism for actin stress
fiber maintenance and repair. Dev. Cell 19, 365–376
Proteome Analysis During Chondrogenesis
10.1074/mcp.M111.010496–10 Molecular & Cellular Proteomics 11.2
